Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasmapheresis and rituximab after kidney transplantation for recurrent focal segmental glomerulosclerosis
RBR-586t2rvRecruiting
- Sponsor
- Hospital do Rim e Hipertensão
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in focal segmental glomerulosclerosis (FSGS) and nephrosis, sponsored by Hospital do Rim e Hipertensão. Started Sep 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
focal segmental glomerulosclerosis (FSGS)nephrosis
Beyond the preview
Go deeper on RBR-586t2rv.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-586t2rv.